StonvexLoading…
StonvexStonvexStonvexReal-time TradingView chart with full indicator set.
Last 7 days, powered by Finnhub. Tap Analyze to classify direction.
Loading latest news…
Pick the depth your tier unlocks. Logged-in Pro/Premium users automatically get the deeper report.
Free preview · 3 reports / hour · No sign-up required
Factor grades, AI Copilot, personalized ranking, and deeper event analysis.
Upgrade to Pro →Share this analysis with other traders
Disclaimer: The content on this page is for informational and educational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any security. Past performance does not guarantee future results. Consult a licensed financial advisor before making any investment decisions.
No sell-side coverage available for CDIO yet.
Common for small-cap names, ETFs, recent IPOs, and ADRs without US-listed sell-side coverage. When analysts publish, ratings appear here within one business day.
| Date | Open | Close | Δ | Vol |
|---|---|---|---|---|
| 05-14 | $1.87 | $1.68 | -10.16% | 0.1M |
| 05-15 | $1.65 | $1.55 | -6.06% | 0.1M |
| 05-18 | $1.55 | $1.39 | -10.32% | 0.1M |
| 05-19 | $1.36 | $1.37 | +0.74% | 0.1M |
| 05-20 | $1.39 | $1.42 | +2.16% | 0.0M |
Indicator values from Polygon. Educational only — single- indicator triggers in isolation are not a complete trading signal.
Cardio Diagnostics Holdings Inc is a medical technology company focused on developing and commercializing epigenetics-based clinical tests for cardiovascular diseases and associated comorbidities by leveraging its Artificial Intelligence (AI)-driven Multi-Omics Engine. The company has developed two clinical products: Epi+Gen CHD and PrecisionCHD, epigenetics-based clinical blood tests capable of assessing risk for a coronary heart disease (CHD) event, including heart attacks. Additionally, its portfolio includes HeartRisk, a cardiovascular disease risk intelligence platform, and CardioInnovate360, a research-use-only solution launched to support the discovery, development, and validation of novel biopharmaceuticals for the assessment and management of cardiovascular diseases.
Documents are served directly from sec.gov / the issuer's website — Stonvex does not proxy or store filings.
Quarterly filings sourced directly from SEC EDGAR. Real-time earnings actuals are in the Earnings panel above.
| Metric | Q1 2026 2026-03-31 | Annual 2025 2025-12-31 | Q3 2025 2025-09-30 | Q2 2025 2025-06-30 |
|---|---|---|---|---|
Revenue | $2.68K | $14.82K | $11.27K | $8.41K |
Operating Income | $-1.78M | $-6.48M | $-5.02M | $-3.31M |
Net Income | $-1.79M | $-6.50M | $-5.03M | $-3.32M |
EPS (Diluted) | $-0.63 | $-3.71 | $-2.91 | $-1.94 |
Total Assets | $9.56M | $7.77M | $8.79M | $10.40M |
Total Liabilities | $655.97K | $793.06K | $637.33K | $671.85K |
Cash & Equivalents | $0.00 | $0.00 | $0.00 | $0.00 |
Free Cash Flow OCF − CapEx | $-1.56M | $-5.91M | $-4.55M | $-3.00M |
Shares Outstanding | 2.96M | 1.83M | 1.77M | 1.74M |